Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.6%

59 terminated/withdrawn out of 287 trials

Success Rate

74.1%

-12.4% vs industry average

Late-Stage Pipeline

22%

62 trials in Phase 3/4

Results Transparency

75%

126 of 169 completed trials have results

Key Signals

24 recruiting126 with results49 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 1

89(38.4%)

Phase 2

75(32.3%)

Phase 3

53(22.8%)

Phase 4

9(3.9%)

N/A

5(2.2%)

Early Phase 1

1(0.4%)

232Total

Phase 1(89)

Phase 2(75)

Phase 3(53)

Phase 4(9)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (287)

Showing 20 of 287 trials

NCT06079372Phase 3Active Not Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

Role: lead

NCT07557420Phase 3Not Yet Recruiting

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Role: lead

NCT06830798Phase 3Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Role: lead

NCT06744647Phase 2Recruiting

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Role: lead

NCT07157787Phase 2Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Role: lead

NCT05556096Phase 3Active Not Recruiting

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Role: lead

NCT07308574Phase 4Recruiting

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Role: lead

NCT05644561Phase 3Active Not Recruiting

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Role: lead

NCT06312644Recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Role: lead

NCT06291376Phase 3Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Role: lead

NCT05389449Phase 3Active Not Recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Role: lead

NCT05746559Phase 3Active Not Recruiting

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Role: lead

NCT07352423Phase 1Recruiting

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants

Role: lead

NCT07221838Phase 4Recruiting

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Role: lead

NCT04543591Phase 3Completed

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Role: lead

NCT05501717Phase 1Active Not Recruiting

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Role: lead

NCT06607627Phase 3Recruiting

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Role: lead

NCT07160608Phase 2Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Role: lead

NCT07037420Phase 2Recruiting

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Role: lead

NCT07081646Phase 1Recruiting

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Role: lead